| 1 |
Bennett JL , O'Connor KC , Bar-Or A , Zamvil SS , Hemmer B , Tedder TF , von Büdingen HC , Stuve O , Yeaman MR , Smith TJ , Stadelmann C . B lymphocytes in neuromyelitis optica. Neurol Neuroimmunol Neuroinflamm, 2015, 2: e104.
doi: 10.1212/NXI.0000000000000104
|
| 2 |
Neuroimmunology Branch, Chinese Society of Immunology . Diagnosis and treatment guidelines for optic neuromyelitis spectrum diseases in China (2021 edition). Zhongguo Shen Jing Mian Yi Xue He Shen Jing Bing Xue Za Zhi, 2021, 28: 423- 436.
URL
|
|
中国免疫学会神经免疫分会. 中国视神经脊髓炎谱系疾病诊断与治疗指南(2021版). 中国神经免疫学和神经病学杂志, 2021, 28: 423- 436.
URL
|
| 3 |
Jarius S , Paul F , Aktas O , Asgari N , Dale RC , de Seze J , Franciotta D , Fujihara K , Jacob A , Kim HJ , Kleiter I , Kümpfel T , Levy M , Palace J , Ruprecht K , Saiz A , Trebst C , Weinshenker BG , Wildemann B . MOG encephalomyelitis: international recommendations on diagnosis and antibody testing. J Neuroinflammation, 2018, 15: 134.
doi: 10.1186/s12974-018-1144-2
|
| 4 |
Kümpfel T , Giglhuber K , Aktas O , Ayzenberg I , Bellmann-Strobl J , Häußler V , Havla J , Hellwig K , Hümmert MW , Jarius S , Kleiter I , Klotz L , Krumbholz M , Paul F , Ringelstein M , Ruprecht K , Senel M , Stellmann JP , Bergh FT , Trebst C , Tumani H , Warnke C , Wildemann B , Berthele A , Neuromyelitis Optica Study Group (NEMOS) . Update on the diagnosis and treatment of neuromyelitis optica spectrum disorders (NMOSD): revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part Ⅱ: attack therapy and long-term management. J Neurol, 2024, 271: 141- 176.
doi: 10.1007/s00415-023-11910-z
|
| 5 |
Jarius S , Aktas O , Ayzenberg I , Bellmann-Strobl J , Berthele A , Giglhuber K , Häußler V , Havla J , Hellwig K , Hümmert MW , Kleiter I , Klotz L , Krumbholz M , Kümpfel T , Paul F , Ringelstein M , Ruprecht K , Senel M , Stellmann JP , Bergh FT , Tumani H , Wildemann B , Trebst C , Neuromyelitis Optica Study Group (NEMOS) . Update on the diagnosis and treatment of neuromyelits optica spectrum disorders (NMOSD): revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part Ⅰ: diagnosis and differential diagnosis. J Neurol, 2023, 270: 3341- 3368.
doi: 10.1007/s00415-023-11634-0
|
| 6 |
Wingerchuk DM , Banwell B , Bennett JL , Cabre P , Carroll W , Chitnis T , de Seze J , Fujihara K , Greenberg B , Jacob A , Jarius S , Lana-Peixoto M , Levy M , Simon JH , Tenembaum S , Traboulsee AL , Waters P , Wellik KE , Weinshenker BG , International Panel for NMO Diagnosis . International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology, 2015, 85: 177- 189.
doi: 10.1212/WNL.0000000000001729
|
| 7 |
Chinese Society of Neuroimmunology . Expert consensus on the detection of antibodies associated with autoimmune diseases of the central nervous system 2022. Zhonghua Shen Jing Ke Za Zhi, 2023, 56: 257- 268.
|
|
中华医学会神经病学分会神经免疫学组. 中枢神经系统自身免疫性疾病相关抗体检测专家共识2022. 中华神经科杂志, 2023, 56: 257- 268.
|
| 8 |
Fu Y , Bi J , Yan Y , Sun X , Li K , Kim SY , Han SM , Zhou L , Li R , Huang Q , Wang N , Lin A , Kim HJ , Qiu W . Rapid immunodot AQP4 assay for neuromyelitis optica spectrum disorder. JAMA Neurol, 2023, 80: 1105- 1112.
doi: 10.1001/jamaneurol.2023.2974
|
| 9 |
Paul F , Marignier R , Palace J , Arrambide G , Asgari N , Bennett JL , Cree BAC , De Sèze J , Fujihara K , Kim HJ , Hornby R , Huda S , Kissani N , Kleiter I , Kuwabara S , Lana-Peixoto M , Law L , Leite MI , Pandit L , Pittock SJ , Quan C , Ramanathan S , Rotstein D , Saiz A , Sato DK , Vaknin-Dembinsky A . International Delphi consensus on the management of AQP4-IgG+NMOSD: recommendations for eculizumab, inebilizumab, and satralizumab. Neurol Neuroimmunol Neuroinflamm, 2023, 10: e200124.
doi: 10.1212/NXI.0000000000200124
|
| 10 |
Aktas O , Smith MA , Rees WA , Bennett JL , She D , Katz E , Cree BAC , N-MOmentum Scientific Group and the N-MOmentum Study Investigators . Serum glial fibrillary acidic protein: aneuromyelitis optica spectrum disorder biomarker. Ann Neurol, 2021, 89: 895- 910.
doi: 10.1002/ana.26067
|
| 11 |
Schindler P , Grittner U , Oechtering J , Leppert D , Siebert N , Duchow AS , Oertel FC , Asseyer S , Kuchling J , Zimmermann HG , Brandt AU , Benkert P , Reindl M , Jarius S , Paul F , Bellmann-Strobl J , Kuhle J , Ruprecht K . Serum GFAP and NfL as disease severity and prognostic biomarkers in patients with aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder. J Neuroinflammation, 2021, 18: 105.
doi: 10.1186/s12974-021-02138-7
|
| 12 |
Aktas O , Hartung HP , Smith MA , Rees WA , Paul F , Marignier R , Bennett JL , Kim HJ , Weinshenker BG , Pittock SJ , Wingerchuk DM , Cutter G , She D , Gunsior M , Cimbora D , Katz E , Cree BA , N-MOmentum Study Investigators . Serum-neurofilament light chain levels at attack predict post attack disability worsening and are mitigated by inebilizumab: analysis of four potential biomarkers in neuromyelitis optica spectrum disorder. J Neurol Neurosurg Psychiatry, 2023, 94: 757- 768.
doi: 10.1136/jnnp-2022-330412
|
| 13 |
Nie T , Blair HA . Inebilizumab: a review in neuromyelitis optica spectrum disorder. CNS Drugs, 2022, 36: 1133- 1141.
doi: 10.1007/s40263-022-00949-7
|
| 14 |
Pittock SJ , Berthele A , Fujihara K , Kim HJ , Levy M , Palace J , Nakashima I , Terzi M , Totolyan N , Viswanathan S , Wang KC , Pace A , Fujita KP , Armstrong R , Wingerchuk DM . Eculizumab in aquaporin-4-positive neuromyelitis optica spectrum disorder. N Engl J Med, 2019, 381: 614- 625.
doi: 10.1056/NEJMoa1900866
|
| 15 |
Wingerchuk DM , Fujihara K , Palace J , Berthele A , Levy M , Kim HJ , Nakashima I , Oreja-Guevara C , Wang KC , Miller L , Shang S , Sabatella G , Yountz M , Pittock SJ , PREVENT Study Group . Long-term safety and efficacy of eculizumab in aquaporin-4 IgG-positive NMOSD. Ann Neurol, 2021, 89: 1088- 1098.
doi: 10.1002/ana.26049
|
| 16 |
Palace J , Wingerchuk DM , Fujihara K , Berthele A , Oreja-Guevara C , Kim HJ , Nakashima I , Levy M , Terzi M , Totolyan N , Viswanathan S , Wang KC , Pace A , Yountz M , Miller L , Armstrong R , Pittock S , PREVENT Study Group . Benefits of eculizumab in AQP4+ neuromyelitis optica spectrum disorder: subgroup analyses of the randomized controlled phase 3 PREVENT trial. Mult Scler Relat Disord, 2021, 47: 102641.
doi: 10.1016/j.msard.2020.102641
|
| 17 |
Sen S , Tuncer A , Terzi M , Bunul SD , Ozen-Acar P , Altunrende B , Ozakbas S , Tutuncu M , Uygunoglu U , Akman-Demir G , Karabudak R , Efendi H , Siva A . Severe disease reactivation in seropositive neuromyelitis optica spectrum disorders patients after stopping eculizumab treatment. Mult Scler Relat Disord, 2023, 79: 104949.
doi: 10.1016/j.msard.2023.104949
|
| 18 |
Cree BAC , Bennett JL , Kim HJ , Weinshenker BG , Pittock SJ , Wingerchuk DM , Fujihara K , Paul F , Cutter GR , Marignier R , Green AJ , Aktas O , Hartung HP , Lublin FD , Drappa J , Barron G , Madani S , Ratchford JN , She D , Cimbora D , Katz E , N-MOmentum Study Investigators . Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial. Lancet, 2019, 394: 1352- 1363.
doi: 10.1016/S0140-6736(19)31817-3
|
| 19 |
Rensel M , Zabeti A , Mealy MA , Cimbora D , She D , Drappa J , Katz E . Long-term efficacy and safety of inebilizumab in neuromyelitis optica spectrum disorder: analysis of aquaporin-4-immunoglobulin G-seropositive participants taking inebilizumab for ≥ 4 years in the N-MOmentum trial. Mult Scler, 2022, 28: 925- 932.
doi: 10.1177/13524585211047223
|
| 20 |
Howard JF Jr , Utsugisawa K , Benatar M , Murai H , Barohn RJ , Illa I , Jacob S , Vissing J , Burns TM , Kissel JT , Muppidi S , Nowak RJ , O'Brien F , Wang JJ , Mantegazza R , REGAIN Study Group . Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study. Lancet Neurol, 2017, 16: 976- 986.
doi: 10.1016/S1474-4422(17)30369-1
|
| 21 |
Kim HJ , Nakashima I , Viswanathan S , Wang KC , Shang S , Miller L , Yountz M , Wingerchuk DM , Pittock SJ , Levy M , Berthele A , Totolyan N , Palace J , Barnett MH , Fujihara K , PREVENT Study Group . Eculizumab in Asian patients with anti-aquaporin-IgG-positive neuromyelitis optica spectrum disorder: a subgroup analysis from the randomized phase 3 PREVENT trial and its open-label extension. Mult Scler Relat Disord, 2021, 50: 102849.
doi: 10.1016/j.msard.2021.102849
|
| 22 |
Nakashima I , Nakahara J , Yokote H , Manabe Y , Okamura K , Hasegawa K , Fujihara K . Long-term safety and effectiveness of eculizumab in patients with aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder: a 2-year interim analysis of post-marketing surveillance in Japan. Ther Adv Neurol Disord, 2023, 16: 1- 13.
|
| 23 |
Agius MA , Klodowska-Duda G , Maciejowski M , Potemkowski A , Li J , Patra K , Wesley J , Madani S , Barron G , Katz E , Flor A . Safety and tolerability of inebilizumab (MEDI-551), an anti-CD19 monoclonal antibody, in patients with relapsing forms of multiple sclerosis: results from a phase 1 randomised, placebo-controlled, escalating intravenous and subcutaneous dose study. Mult Scler, 2019, 25: 235- 245.
doi: 10.1177/1352458517740641
|
| 24 |
Flanagan EP , Levy M , Katz E , Cimbora D , Drappa J , Mealy MA , She D , Cree BAC . Inebilizumab for treatment of neuromyelitis optica spectrum disorder in patients with prior rituximab use from the N-MOmentum Study. Mult Scler Relat Disord, 2022, 57: 103352.
doi: 10.1016/j.msard.2021.103352
|
| 25 |
Bennett JL , Aktas O , Rees WA , Smith MA , Gunsior M , Yan L , She D , Cimbora D , Pittock SJ , Weinshenker BG , Paul F , Marignier R , Wingerchuk D , Cutter G , Green A , Hartung HP , Kim HJ , Fujihara K , Levy M , Katz E , Cree BAC , N-MOmentum Study Investigators . Association between B-cell depletion and attack risk in neuromyelitis optica spectrum disorder: an exploratory analysis from N-MOmentum, a double-blind, randomised, placebo-controlled, multicentre phase 2/3 trial. EBioMedicine, 2022, 86: 104321.
doi: 10.1016/j.ebiom.2022.104321
|
| 26 |
Kim HJ , Aktas O , Patterson KR , Korff S , Kunchok A , Bennett JL , Weinshenker BG , Paul F , Hartung HP , Cimbora D , Smith MA , Mittereder N , Rees WA , She D , Cree BAC . Inebilizumab reduces neuromyelitis optica spectrum disorder risk independent of FCGR3A polymorphism. Ann Clin Transl Neurol, 2023, 10: 2413- 2420.
doi: 10.1002/acn3.51911
|
| 27 |
Igawa T , Ishii S , Tachibana T , Maeda A , Higuchi Y , Shimaoka S , Moriyama C , Watanabe T , Takubo R , Doi Y , Wakabayashi T , Hayasaka A , Kadono S , Miyazaki T , Haraya K , Sekimori Y , Kojima T , Nabuchi Y , Aso Y , Kawabe Y , Hattori K . Antibody recycling by engineered pH-dependent antigen binding improves the duration of antigen neutralization. Nat Biotechnol, 2010, 28: 1203- 1207.
doi: 10.1038/nbt.1691
|
| 28 |
Yamamura T , Kleiter I , Fujihara K , Palace J , Greenberg B , Zakrzewska-Pniewska B , Patti F , Tsai CP , Saiz A , Yamazaki H , Kawata Y , Wright P , De Seze J . Trial of satralizumab in neuromyelitis optica spectrum disorder. N Engl J Med, 2019, 381: 2114- 2124.
doi: 10.1056/NEJMoa1901747
|
| 29 |
Traboulsee A , Greenberg BM , Bennett JL , Szczechowski L , Fox E , Shkrobot S , Yamamura T , Terada Y , Kawata Y , Wright P , Gianella-Borradori A , Garren H , Weinshenker BG . Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial. Lancet Neurol, 2020, 19: 402- 412.
doi: 10.1016/S1474-4422(20)30078-8
|
| 30 |
Kleiter I , Traboulsee A , Palace J , Yamamura T , Fujihara K , Saiz A , Javed A , Mayes D , Büdingen HV , Klingelschmitt G , Stokmaier D , Bennett JL . Long-term efficacy of satralizumab in AQP4-IgG-seropositive neuromyelitis optica spectrum disorder from SAkuraSky and SAkuraStar. Neurol Neuroimmunol Neuroinflamm, 2022, 10: e200071.
|
| 31 |
Lennon-Chrimes S , Baumann HS , Klingelschmitt G , Kou X , Anania VG , Ito H , von Budingen HC . Characterisation of the PK and PD of satralizumab, a recycling antibody, to Support Q4W dosing in patients with NMOSD. Neurology, 2020, 94
|
| 32 |
Yamamura T , Weinshenker B , Yeaman MR , De Seze J , Patti F , Lobo P , von Büdingen HC , Kou X , Weber K , Greenberg B . Long-term safety of satralizumab in neuromyelitis optica spectrum disorder (NMOSD) from SAkuraSky and SAkuraStar. Mult Scler Relat Disord, 2022, 66: 104025.
doi: 10.1016/j.msard.2022.104025
|
| 33 |
Vu T , Ortiz S , Katsuno M , Annane D , Mantegazza R , Beasley KN , Aguzzi R , Howard JF Jr . Ravulizumab pharmacokinetics and pharmacodynamics in patients with generalized myasthenia gravis. J Neurol, 2023, 270: 3129- 3137.
doi: 10.1007/s00415-023-11617-1
|
| 34 |
Pittock SJ , Barnett M , Bennett JL , Berthele A , de Sèze J , Levy M , Nakashima I , Oreja-Guevara C , Palace J , Paul F , Pozzilli C , Yountz M , Allen K , Mashhoon Y , Kim HJ . Ravulizumab in aquaporin-4-positive neuromyelitis optica spectrum disorder. Ann Neurol, 2023, 93: 1053- 1068.
doi: 10.1002/ana.26626
|